Literature DB >> 3166359

Bone penetration of enoxacin in patients with and without osteomyelitis.

I W Fong1, B R Rittenhouse, M Simbul, A C Vandenbroucke.   

Abstract

Enoxacin concentrations in bone were measured in 24 patients without infection and in 7 with osteomyelitis after one or two doses of 400 mg of enoxacin administered orally or intravenously. Enoxacin concentrations were measured in serum and bone (cortical and cancellous) by high-pressure liquid chromatography. The mean concentration in serum was 2.4 +/- 1.0 micrograms/ml (range, 1.3 to 5.2 micrograms/ml) and was highest after two intravenous doses (3.1 +/- 0.9 micrograms/ml). The mean concentration in cortical bone was 1.0 +/- 0.9 micrograms/g (range, 0.4 to 4.8 micrograms/g) and was highest in patients with osteomyelitis (1.3 +/- 1.6 micrograms/g), but this was not statistically significant. The concentration of enoxacin in cancellous bone was significantly higher than that in cortical bone, with a penetration of 82 versus 40%. Oral enoxacin in practical doses can provide significant levels in bone, and further studies are warranted to determine its therapeutic efficacy in osteomyelitis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3166359      PMCID: PMC172291          DOI: 10.1128/AAC.32.6.834

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Experimental osteomyelitis. II. Therapeutic trials and measurement of antibiotic levels in bone.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

2.  In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; U Ullmann
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

3.  Pharmacokinetics and tolerance of enoxacin in healthy volunteers administered at a dosage of 400 mg twice daily for 14 days.

Authors:  S E Tsuei; A S Darragh; I Brick
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

4.  The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers.

Authors:  R Wolf; R Eberl; A Dunky; N Mertz; T Chang; J R Goulet; J Latts
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

5.  In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.

Authors:  S Nakamura; A Minami; H Katae; S Inoue; J Yamagishi; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

6.  Penetration of enoxacin into bronchial secretions.

Authors:  I W Fong; A Vandenbroucke; M Simbul
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

7.  In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

8.  Enoxacin: worldwide in-vitro activity against 22451 clinical isolates.

Authors:  C Siporin; G Towse
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

9.  Ciprofloxacin concentrations in bone and muscle after oral dosing.

Authors:  I W Fong; W H Ledbetter; A C Vandenbroucke; M Simbul; V Rahm
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

  9 in total
  4 in total

Review 1.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

2.  [Enoxacin concentration in bone tissue].

Authors:  D Adam; K Weismeier; F Sörgel; J Zürcher
Journal:  Infection       Date:  1989       Impact factor: 3.553

Review 3.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.